Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Estimate the efficiency of a strategy of premature screening of the maternal anaemia during the first quarter of pregnancy versus the usual strategy of screening of the anaemia during the sixth month.
A part of the patient will have a NFS and dosage of the cast-iron, during the results of the beginning of the pregnancy at the first quarter.
The other part of the patients will have a NFS and at the first quater of the pregnancy.
All the patient will have a NFS at the results of the sixth month of the pregnancy.
A NFS will be done during the results at the end of the pregnancy like we do now.
Then a NFS at 48 hours after the birth. A treatment with iron will be done and according to the results
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NFS and iron in the first quater | Experimental | first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery. |
|
| No NFS and iron in the first quater | Experimental | second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| dosage of the NFS and iron | Biological | a blood test will be made. |
|
| Measure | Description | Time Frame |
|---|---|---|
| primary outcomes: is the rate of heamophilia at the end of the pregnancy. | six months |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary outcomes: - the percent of treatment of intravenous irons during the pregnancy and the following layers. - the percent of transfusion and the following layers. | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vincelot anne, MD | Limoges UH | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU limoges | Limoges | Limousin | 87000 | France |
Not provided
| ID | Term |
|---|---|
| D000740 | Anemia |
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007501 | Iron |
| ID | Term |
|---|---|
| D019216 | Metals, Heavy |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D028561 | Transition Elements |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D008670 |
| Metals |